Vascular Improvement With Olmesartan Medoxomil Study

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Treatments: Amlodipine; Atenolol; Hydralazine; Hydrochlorothiazide; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Male or female

• 18-75 years of age

• Mean seated diastolic BP 90-109 or mean seated systolic BP of 140-179

Exclusion Criteria:

• Secondary hypertension

• Renal disease

• Diabetes mellitus

• Serum creatinine >3.0 mg/dL

• Hemoglobin <10 mg/dL (males) or <9mg/dL (females)

• WBC count <2000 cells/mL

• Platelet count <100,000 cells/mL

• Either ALT & AST >2.5 x upper limit of normal

• BMI >35 kg/m2

• TIA or cerebrovascular attack within 3 months of study entry